<DOC>
	<DOCNO>NCT02706405</DOCNO>
	<brief_summary>This phase Ib trial study whether anti-cluster differentiation ( CD ) 19-chimeric antigen receptor ( CAR ) lentiviral vector-transduced autologous T cell ( JCAR014 ) durvalumab safe combination work together treat patient non-Hodgkin lymphoma returned period improvement respond previous treatment . JCAR014 make patient ' immune cell ( T cell ) new gene add laboratory , program kill lymphoma cell . Durvalumab type drug call monoclonal antibody , target PD-L1 may help immune cell attack cancer cell effectively thus help JCAR014 work well .</brief_summary>
	<brief_title>JCAR014 Durvalumab Treating Patients With Relapsed Refractory B-cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate safety JCAR014 combination durvalumab adult patient relapsed/refractory ( R/R ) B-cell non-Hodgkin lymphoma ( NHL ) . II . To determine maximum tolerate dose ( MTD ) durvalumab combination JCAR014 . III . To characterize pharmacokinetic ( PK ) profile JCAR014 . SECONDARY OBJECTIVES : I . To assess antitumor activity JCAR014 combination durvalumab R/R B-cell NHL . II . To estimate duration response ( DOR ) , progression-free survival ( PFS ) , overall survival ( OS ) patient treat JCAR014 combination durvalumab . III . To characterize PK profile durvalumab . IV . To assess immunogenicity JCAR014 durvalumab . TERTIARY OBJECTIVES : I . To assess pharmacodynamic effect JCAR014 durvalumab blood within tumor . OUTLINE : This dose-escalation study durvalumab administer single fix dose JCAR014 . Patients assign 1 2 treatment arm , list Groups 1 2 . LYMPHODEPLETING CHEMOTHERAPY : All patient receive cyclophosphamide intravenously ( IV ) day -5 fludarabine phosphate IV day -4 -2 . GROUP I : Patients receive JCAR014 IV 20-30 minute day 0 durvalumab IV 60 minute day 28 ( may occur early day 21 ) every 4 week 10 dos absence disease progression unacceptable toxicity . GROUP II : Patients receive durvalumab IV 60 minute day -1 28 , JCAR014 IV 20-30 minute day 0 . Patients may receive durvalumab IV 60 minute every 4 week 11 dos absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 , 2 , 3 month , every 3 month 1 year , periodically least 15 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Relapsed refractory diffuse large Bcell lymphoma ( DLBCL ) otherwise specify ( NOS ) , primary mediastinal Bcell lymphoma ( PMBCL ) , DLBCL transform indolent histology one following : Persistent disease firstline chemoimmunotherapy Relapse firstline chemoimmunotherapy eligible autologous hematopoietic stem cell transplant ( HCT ) Relapse persistent disease least two line therapy autologous HCT Ability understand provide inform consent Subjects know active central nervous system ( CNS ) involvement malignancy ; subject prior CNS disease effectively treat eligible treatment complete least 3 month prior enrollment evidence disease stable abnormality repeat image Planned use corticosteroid ( &gt; 10 mg/day prednisone equivalent ) systemic immunosuppression within 4 day prior leukapheresis ; topical and/or inhale steroid permit Prior treatment CD19 CAR Tcell therapy Prior allogeneic HCT Known active hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) infection Pregnant breastfeeding woman Prior treatment program cell death ( PD ) 1 , PDligand ( L ) 1 , cytotoxic T lymphocyteassociated protein 4 ( CTLA 4 ) target therapy , tumor necrosis factor receptor superfamily ( TNFRSF ) agonists include CD134 ( OX40 ) , CD27 , CD137 ( 41BB ) , CD357 ( glucocorticoidinduced tumor necrosis factor receptor familyrelated protein [ GITR ] ) Active prior document autoimmune inflammatory disorder within 3 year prior plan start treatment ; follow exception criterion : Vitiligo Alopecia Hypothyroidism ( e.g. , follow Hashimoto syndrome ) stable hormone replacement Psoriasis require systemic treatment Other condition consider low risk serious deterioration principal investigator ( PI ) History one follow cardiovascular condition within past 6 month : class III IV heart failure define New York Heart Association ( NYHA ) , cardiac angioplasty stenting , myocardial infarction , unstable angina ; history clinically significant cardiac disease , opinion PI designee , contraindication lymphodepleting chemotherapy , JCAR014 infusion , durvalumab infusion also exclude History presence clinically relevant CNS pathology History solid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PD-L1</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
</DOC>